their effectiveness but shrinking their addressable markets. Drug companies will need to adapt their marketing strategies accordingly. Novartis CEO Joe Jimenez called out the explosion in DNA sequencing as a driver for R&D productivity "allowing new areas of discovery that have never been possible before."